{"id":59821,"date":"2026-06-04T22:49:31","date_gmt":"2026-06-04T13:49:31","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4892\/"},"modified":"2026-08-23T13:34:44","modified_gmt":"2026-08-23T04:34:44","slug":"company-4892","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4892\/","title":{"rendered":"CYFUSE BIOMEDICAL K K"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4892","DATE":"2026-01-09","longName":"Cyfuse Biomedical K.K.","company_name_ja":"","fullTimeEmployees":23,"address":"","phone":"","website":"https:\/\/www.cyfusebio.com","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":603,"financialCurrency":"","marketCap":5354,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":230999000,"OperatingIncome":-828179000,"operatingMargins":-358.51999999999998,"NetIncome":-763843000,"profitMargins":-330.67000000000002,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-27.699999999999999,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:54:18.783316\", \"ticker\": \"4892\", \"ticker_full\": \"4892.T\", \"company_name\": \"CYFUSE BIOMEDICAL K K\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 518.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 25.04, \"institution_pct\": 2.21, \"major_holders\": [{\"label\": \"\", \"value\": 25.04}, {\"label\": \"\", \"value\": 2.21}, {\"label\": \"\", \"value\": 2.95}, {\"label\": \"\", \"value\": 1.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of drugs. Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:00:00.073928\", \"ticker\": \"4892\", \"ticker_full\": \"4892.T\", \"company_name\": \"CYFUSE BIOMEDICAL K K\", \"company_info\": {\"name_en\": \"CYFUSE BIOMEDICAL K K\", \"long_name\": \"Cyfuse Biomedical K.K.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.cyfusebio.com\", \"employees\": 23, \"country\": \"Japan\", \"city\": \"Minato\", \"address\": \"South Tower, Sumitomo Fudosan Tokyo Mita\", \"description\": \"Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of drugs. Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 561.8, \"deviation\": 0.57, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 534.32, \"deviation\": 5.74, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 560.13, \"deviation\": 0.87, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 596.8, \"deviation\": -5.33, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 230999000.0, \"revenue_fmt\": \"\u00a52\u5104\", \"gross_profit\": 113894000.0, \"gross_profit_fmt\": \"\u00a51\u5104\", \"operating_income\": -828179000.0, \"operating_income_fmt\": \"-\u00a58\u5104\", \"ebit\": -747022000.0, \"ebit_fmt\": \"-\u00a57\u5104\", \"net_income\": -763843000.0, \"net_income_fmt\": \"-\u00a58\u5104\", \"eps\": 0, \"operating_margin\": -358.52, \"total_assets\": 4266026000.0, \"total_assets_fmt\": \"\u00a543\u5104\", \"total_equity\": 2757626000.0, \"total_equity_fmt\": \"\u00a528\u5104\", \"total_debt\": 1312000000.0, \"total_debt_fmt\": \"\u00a513\u5104\", \"total_cash\": 3726535000.0, \"total_cash_fmt\": \"\u00a537\u5104\", \"equity_ratio\": 64.64, \"de_ratio\": 0.48, \"current_ratio\": 4.54, \"operating_cf\": -534793000.0, \"operating_cf_fmt\": \"-\u00a55\u5104\", \"investing_cf\": -397564000.0, \"investing_cf_fmt\": \"-\u00a54\u5104\", \"financing_cf\": 1256323000.0, \"financing_cf_fmt\": \"\u00a513\u5104\", \"free_cf\": -582357000.0, \"free_cf_fmt\": \"-\u00a56\u5104\", \"net_margin\": -330.67, \"roe\": -27.7, \"roa\": -17.91}, {\"year\": 2024, \"revenue\": 54446000.0, \"revenue_fmt\": \"\u00a554.4M\", \"gross_profit\": 16849000.0, \"gross_profit_fmt\": \"\u00a516.8M\", \"operating_income\": -896133000.0, \"operating_income_fmt\": \"-\u00a59\u5104\", \"ebit\": -860233000.0, \"ebit_fmt\": \"-\u00a59\u5104\", \"net_income\": -872238000.0, \"net_income_fmt\": \"-\u00a59\u5104\", \"eps\": -108.34, \"operating_margin\": -1645.91, \"total_assets\": 3518001000.0, \"total_assets_fmt\": \"\u00a535\u5104\", \"total_equity\": 2542405000.0, \"total_equity_fmt\": \"\u00a525\u5104\", \"total_debt\": 852800000.0, \"total_debt_fmt\": \"\u00a59\u5104\", \"total_cash\": 3052570000.0, \"total_cash_fmt\": \"\u00a531\u5104\", \"equity_ratio\": 72.27, \"de_ratio\": 0.34, \"current_ratio\": 5.0, \"operating_cf\": -760553000.0, \"operating_cf_fmt\": \"-\u00a58\u5104\", \"investing_cf\": -8637000.0, \"investing_cf_fmt\": \"-\u00a58.6M\", \"financing_cf\": -52012000.0, \"financing_cf_fmt\": \"-\u00a552.0M\", \"free_cf\": -769099000.0, \"free_cf_fmt\": \"-\u00a58\u5104\", \"net_margin\": -1602.02, \"roe\": -34.31, \"roa\": -24.79}, {\"year\": 2023, \"revenue\": 61112000.0, \"revenue_fmt\": \"\u00a561.1M\", \"gross_profit\": 37743000.0, \"gross_profit_fmt\": \"\u00a537.7M\", \"operating_income\": -697437000.0, \"operating_income_fmt\": \"-\u00a57\u5104\", \"ebit\": -576413000.0, \"ebit_fmt\": \"-\u00a56\u5104\", \"net_income\": -589211000.0, \"net_income_fmt\": \"-\u00a56\u5104\", \"eps\": -75.42, \"operating_margin\": -1141.24, \"total_assets\": 4214809000.0, \"total_assets_fmt\": \"\u00a542\u5104\", \"total_equity\": 3203469000.0, \"total_equity_fmt\": \"\u00a532\u5104\", \"total_debt\": 913000000.0, \"total_debt_fmt\": \"\u00a59\u5104\", \"total_cash\": 3873773000.0, \"total_cash_fmt\": \"\u00a539\u5104\", \"equity_ratio\": 76.01, \"de_ratio\": 0.29, \"current_ratio\": 5.98, \"operating_cf\": -562296000.0, \"operating_cf_fmt\": \"-\u00a56\u5104\", \"investing_cf\": -19474000.0, \"investing_cf_fmt\": \"-\u00a519.5M\", \"financing_cf\": 18236000.0, \"financing_cf_fmt\": \"\u00a518.2M\", \"free_cf\": -581770000.0, \"free_cf_fmt\": \"-\u00a56\u5104\", \"net_margin\": -964.15, \"roe\": -18.39, \"roa\": -13.98}, {\"year\": 2022, \"revenue\": 374477000.0, \"revenue_fmt\": \"\u00a54\u5104\", \"gross_profit\": 241495000.0, \"gross_profit_fmt\": \"\u00a52\u5104\", \"operating_income\": -425090000.0, \"operating_income_fmt\": \"-\u00a54\u5104\", \"ebit\": -444019000.0, \"ebit_fmt\": \"-\u00a54\u5104\", \"net_income\": -473962000.0, \"net_income_fmt\": \"-\u00a55\u5104\", \"eps\": -177.67, \"operating_margin\": -113.52, \"total_assets\": 4815337000.0, \"total_assets_fmt\": \"\u00a548\u5104\", \"total_equity\": 3769801000.0, \"total_equity_fmt\": \"\u00a538\u5104\", \"total_debt\": 908144000.0, \"total_debt_fmt\": \"\u00a59\u5104\", \"total_cash\": 4437307000.0, \"total_cash_fmt\": \"\u00a544\u5104\", \"equity_ratio\": 78.29, \"de_ratio\": 0.24, \"current_ratio\": 6.69, \"operating_cf\": -403596000.0, \"operating_cf_fmt\": \"-\u00a54\u5104\", \"investing_cf\": -430674000.0, \"investing_cf_fmt\": \"-\u00a54\u5104\", \"financing_cf\": 2658538000.0, \"financing_cf_fmt\": \"\u00a527\u5104\", \"free_cf\": -631872000.0, \"free_cf_fmt\": \"-\u00a56\u5104\", \"net_margin\": -126.57, \"roe\": -12.57, \"roa\": -9.84}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 285.52, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-59821","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CYFUSE BIOMEDICAL K K - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4892\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/\",\"name\":\"CYFUSE BIOMEDICAL K K - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:49:31+00:00\",\"dateModified\":\"2026-08-23T04:34:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4892\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CYFUSE BIOMEDICAL K K\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CYFUSE BIOMEDICAL K K - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4892\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/","url":"https:\/\/japanir.jp\/en\/company\/company-4892\/","name":"CYFUSE BIOMEDICAL K K - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:49:31+00:00","dateModified":"2026-08-23T04:34:44+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4892\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"CYFUSE BIOMEDICAL K K"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/59821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=59821"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=59821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}